Video
Author(s):
Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.
Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Neoadjuvant Therapy Selection: Are Abbreviated Regimens an Option in HER2+ Breast Cancer?
Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management
De-Escalation Strategies, Biomarkers Could Refine Treatment Algorithm for Early-Stage HER2+ Breast Cancer
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC